Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pulmonx raises $32mm through its Series C venture round

Executive Summary

Two years after withdrawing its IPO, Pulmonx (devices to diagnose and treat pulmonary disorders) has raised $32mm through its Series C venture round. New backers HealthCap and Kleiner Perkins Caufield & Byers, which co-led the financing and each contribute a board member, were joined by current shareholders DeNovo Ventures, Latterell Venture Partners, MedVenture Associates, Montreux Equity Partners, and Posco BioVentures and nine undisclosed investors. The company is preparing for the commercial launch of its Chartis pulmonary assessment system and Zephyr endobronchial valve for emphysema.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies